Equity
€284,725 ▼ 1.6%
MAXPHARMA paid out €20,000 in dividends. That is 131% of the 2025 profit.
MAXPHARMA
Lifetime
20 annual accounts with figures on one time axis, 26 filings since 2000peak €225,463 (2021)
€113,032▲ 27.5%
lowest -€25,208 (2024)
€15,264▲ €40,472
peak €334,157 (2021)
€284,725▼ 1.6%
€142,260▲ 30.9%
peak 2.7 FTE (2024)
1.9 FTE▼ 29.6%
Board5 names since 2018
1 director
Owners
100%
Documentsfilings and deeds
01-07-202630 days before the deadline
2025abbreviated format
Gross margin from €88,665 to €113,032Back to profit: €15,264Staff from 2.7 FTE to 1.9 FTERegistered office moved from Wavre to Etterbeek 24-01Dividend €20,000Debts from €108,713 to €142,260
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 17,044 companies had the same profile as MAXPHARMA has now. Each dot stands for 43 companies, two years later.
94.3%
were still trading
5.0%
stopped another way
0.5%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,044 companies, not a prediction for MAXPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Managing director,
- 100%score equity €141,142 (2025) · 2025 annual accounts of
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0471830863
Registered office moved from Wavre to Etterbeek
New registered office: chaussée de Wavre n°736, 1040 ETTERBEEK · Previous registered office: rue des Templiers 73, 1301 Wavre · Resignation: (managing director) · General meeting of 01-01-2025 · Gazette deed
New managing director
appointed, resigned · Permanent representative: · Director discharge: · General meeting of 10-02-2022 · Gazette deed
Resignation: (managing director)
General meeting of 07-05-2021 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| MAXPHARMA Etterbeek | €426,986 | €113,032 | 66.7% | 1.9 |
| APOTHEEK MEES NIEUWRODE Holsbeek | €441,980 | €134,117 | -1.5% | 1.9 |
| OFFIPHARMA Froidchapelle | €399,757 | €124,712 | 65.3% | 1.5 |
| COBEA PHARMA Villers-la-Ville | €362,823 | €144,021 | 40.4% | 2 |
| APOTHEEK MEES HAACHT STATION Haacht | €499,951 | €137,247 | 37.9% | 1.6 |
| POGGE Schaerbeek | €285,910 | €128,031 | 34.5% | 2 |
| PHARMACIE DERASSE La Louvière | €387,571 | €148,815 | 26.6% | 1.8 |
These companies have the same main activity as MAXPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €286,000 and €500,000, founded between 2001 and 2005.
Official details
Source: KBO- Status
- Active since 05-05-2000Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.098.675.3701040 Etterbeek, since 18-12-2001
- Financial year end
- 31 December
- Peppol
- Reachable since 18-12-2025
Annual accounts 2025
- ≈ €530,000estimated
- €426,986▲ 7.2%
- Employeeson 31-12-2025
- 2▼ 60.0%
- Filing
- Filed on 01-07-2026, 30 days before the end of the filing period
Insights on MAXPHARMA
MAXPHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €78,126 in 2006 to €113,032 in 2025.
holds all the shares. In January 2025, the Official Gazette published the appointment of as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about MAXPHARMA
- What is the company number of MAXPHARMA?
- The company number of MAXPHARMA is 0471.830.863. The VAT number is the same number with BE in front: BE 0471.830.863.
- Where is MAXPHARMA based?
- The registered office is at Steenweg op Waver 736, 1040 Etterbeek.Company details
- What does MAXPHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of MAXPHARMA?
- MAXPHARMA is a public limited company (NV).
- When was MAXPHARMA founded?
- MAXPHARMA was founded on 05-05-2000.
- Is MAXPHARMA still active?
- Yes, MAXPHARMA is an active enterprise in the KBO register.
- How many employees does MAXPHARMA have?
- MAXPHARMA had an average of 1.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does MAXPHARMA fall under?
- In its 2025 annual accounts, MAXPHARMA states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of MAXPHARMA?
- The turnover in financial year 2025 is ≈ €530,000. This figure is estimated from the gross margin of €113,032 and 52 comparable companies (NACE 477). It probably lies between €360,000 and €990,000.
- Is MAXPHARMA profitable?
- In financial year 2025, MAXPHARMA made a profit of €15,264.
- Where can I find the annual accounts of MAXPHARMA?
- MAXPHARMA filed 26 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of MAXPHARMA due?
- MAXPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.